T-cell based immunotherapies hold great promise as a powerful new approach to treat NSCLC as treatment with antibodies interrupting immune checkpoint PD-1/PD-L1 has shown great clinical benefit in NSCLC [5–7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.